Research programme: NAD(P)H oxidase inhibitors - vasopharm BIOTECH

Drug Profile

Research programme: NAD(P)H oxidase inhibitors - vasopharm BIOTECH

Alternative Names: VAS 2870

Latest Information Update: 01 Jun 2011

Price : $50

At a glance

  • Originator vasopharm BIOTECH
  • Class
  • Mechanism of Action NADH oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical Peripheral arterial occlusive disorders

Most Recent Events

  • 31 May 2011 Preclinical development is ongoing in Germany
  • 16 Feb 2007 VAS 2870 is still in active development
  • 19 Sep 2005 Preclinical trials in Peripheral arterial occlusive disorders in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top